PAION is a specialty pharmaceutical company that develops innovative products for sedation and anesthesia including commercialization.  

 

Learn more About PAION

Remimazolam

PAION's lead compound, Remimazolam, is an ultra-short-acting intravenous sedative and anesthetic that is currently in Phase III clinical development for procedural sedation and general anesthesia. Remimazolam has been investigated in more than 1,000 patients worldwide. 

PAION's Remimazolam

news

06/24/2016

Press Release: PAION grants Cosmo Pharmaceuticals Remimazolam license in the...

PAION grants Cosmo Pharmaceuticals Remimazolam license in the...

Read more
06/24/2016

Ad hoc release: PAION grants Cosmo Pharmaceuticals Remimazolam license in the...

PAION grants Cosmo Pharmaceuticals Remimazolam license in the...

Read more
06/19/2016

Press Release: PAION reports positive remimazolam headline data in pivotal U.S....

PAION reports positive remimazolam headline data in pivotal U.S....

Read more
06/24/2016

Press Release: PAION grants Cosmo Pharmaceuticals Remimazolam license in the...

PAION grants Cosmo Pharmaceuticals Remimazolam license in the...

Read more
06/19/2016

Press Release: PAION reports positive remimazolam headline data in pivotal U.S....

PAION reports positive remimazolam headline data in pivotal U.S....

Read more
04/11/2016

Press Release: PAION successfully completes patient recruitment in Phase III...

PAION successfully completes patient recruitment in Phase III...

Read more

PAION Chart